181 related articles for article (PubMed ID: 16859314)
21. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
22. 3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method.
Temiz-Arpaci O; Tekiner-Gulbas B; Yildiz I; Aki-Sener E; Yalcin I
Bioorg Med Chem; 2005 Dec; 13(23):6354-9. PubMed ID: 15993083
[TBL] [Abstract][Full Text] [Related]
23. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
24. Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion.
Elnagar AY; Wali VB; Sylvester PW; El Sayed KA
Bioorg Med Chem; 2010 Jan; 18(2):755-68. PubMed ID: 20022507
[TBL] [Abstract][Full Text] [Related]
25. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
26. Pharmacophore identification and validation study of CK2 inhibitors using CoMFA/CoMSIA.
Morshed MN; Muddassar M; Pasha FA; Cho SJ
Chem Biol Drug Des; 2009 Aug; 74(2):148-58. PubMed ID: 19563463
[TBL] [Abstract][Full Text] [Related]
27. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
28. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
Sissi C; Moro S; Richter S; Gatto B; Menta E; Spinelli S; Krapcho AP; Zunino F; Palumbo M
Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029
[TBL] [Abstract][Full Text] [Related]
29. A comparative molecular field and comparative molecular similarity indices analyses (CoMFA and CoMSIA) of N-phenyl-N'-(2-chloroethyl)ureas targeting the colchicine-binding site as anticancer agents.
Fortin S; Labrie P; Moreau E; Wei L; Kotra LP; C-Gaudreault R
Bioorg Med Chem; 2008 Feb; 16(4):1914-26. PubMed ID: 18023585
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.
Hasinoff BB; Wu X; Krokhin OV; Ens W; Standing KG; Nitiss JL; Sivaram T; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Mol Pharmacol; 2005 Mar; 67(3):937-47. PubMed ID: 15602006
[TBL] [Abstract][Full Text] [Related]
31. QSAR analysis of 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines with anticancer activity.
Atanasova M; Ilieva S; Galabov B
Eur J Med Chem; 2007 Sep; 42(9):1184-92. PubMed ID: 17408810
[TBL] [Abstract][Full Text] [Related]
32. The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane.
Hasinoff BB; Tran KT
J Inorg Biochem; 1999; 77(3-4):257-9. PubMed ID: 10643663
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
Nayyar A; Monga V; Malde A; Coutinho E; Jain R
Bioorg Med Chem; 2007 Jan; 15(2):626-40. PubMed ID: 17107805
[TBL] [Abstract][Full Text] [Related]
34. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
Zhou YJ; Zhu LP; Tang Y; Ye DY
Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
[TBL] [Abstract][Full Text] [Related]
35. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
36. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
Zhang H; Li H; Ma Q
J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
[TBL] [Abstract][Full Text] [Related]
37. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
38. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.
Chaudhaery SS; Roy KK; Saxena AK
J Chem Inf Model; 2009 Jun; 49(6):1590-601. PubMed ID: 19441865
[TBL] [Abstract][Full Text] [Related]
39. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
AbdulHameed MD; Hamza A; Liu J; Zhan CG
J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
[TBL] [Abstract][Full Text] [Related]
40. Predicting anti-cancer activity of quinoline derivatives: CoMFA and CoMSIA approach.
Vaidya A; Jain AK; Kumar P; Kashaw SK; Agrawal RK
J Enzyme Inhib Med Chem; 2011 Dec; 26(6):854-61. PubMed ID: 21476832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
